Interventional Oncology Ablation Market Analysis & Forecast: 2025-2032

Interventional Oncology Ablation Market Size and Forecast – 2025-2032

The Interventional Oncology Ablation Market is estimated to be valued at USD 631.0 Mn in 2025 and is expected to reach USD 1,131.5 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Key Takeaways:               

• By Technology, the Radiofrequency Ablation is dominating the overall market with a share of 36.2%. This technology is widely used due to its effectiveness in treating various cancers, particularly liver and kidney tumors.
• On the basis of Indication, the Liver Cancer segment leads the overall market growth owing to the growing prevalence of liver malignancies.
• Based on End User, Hospital segment acquires the largest share as they are equipped with advanced imaging technologies.
• On the basis of Region, North America acquires the dominant share of 33.5% owing to the growing product approvals across United States and Canada.

Market Overview

The market expands because more people develop cancer combined with better technology and increasing adoption of procedures that avoid extensive surgical approaches. RFA and MWA serve as popular ablation treatments for patients who cannot undergo surgery because of tumor size and location together with their general health condition. The widespread use of RFA persists because medical practitioners feel comfortable with familiar procedures although MWA demonstrates value in its rapid delivery of wide-reaching treatment fields. Treatment accuracy and safety receive improvement through the use of advanced imaging and navigation systems. MD Anderson and Charité Hospital lead developments in cancer research while advancing comprehensive ablation implementation within cancer care at their facilities.

Current Events and their Impact on the Interventional Oncology Ablation Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Role of AI (Artificial Intelligence) in Interventional Oncology Ablation Market

AI integration in the Interventional Oncology Ablation Market is transforming how cancer treatments are planned, executed, and monitored. The use of Artificial Intelligence (AI) in this sector is primarily focused on improving the precision, efficiency, and outcomes of ablation procedures. For instance, in September 2023, the Food and Drug Administration (FDA) granted 510(k) clearance for VisAble.IO (TechsoMed), an AI-powered software designed to enhance real-time imaging guidance during liver tumor ablation procedures. The software supports ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) to improve procedural accuracy.

Reimbursement Scenario in Interventional Oncology Ablation Market

In the U.S., Medicare provides reimbursement for radiofrequency ablation (RFA) for liver cancer treatment under the Medicare Physician Fee Schedule (MPFS). This reimbursement covers the costs of RFA procedures when used for the treatment of hepatocellular carcinoma (HCC) in patients who are not candidates for surgery or liver transplant. Medicare reimburses approximately $1,500 to $2,500 for an RFA procedure depending on the location and complexity of the treatment.

Segmental Analysis

To learn more about this report, Request sample copy

Interventional Oncology Ablation Market Analysis & Forecast, By Technology: Radio frequency ablation (RFA) segment Dominates the market

The Radio frequency ablation (RFA) segment leads as the principal part of the Interventional Oncology Ablation Market Share in 2025 with a projected share of more than 42.5%. The medical procedure finds extensive application in liver and renal tumor ablation because of its common handling mechanism and affordable cost. MD Anderson Cancer Center and other institutions have established universal protocols for performing RFA procedures on early-stage hepatocellular carcinoma. For instance, in July 2024, Stryker launched MultiGen 2 Radiofrequency (RF) Generator. This technology provides physicians with the efficiency, control and reliability they need when performing RF ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain.

Interventional Oncology Ablation Market Analysis & Forecast, By Indication: Rising Cancer Incidence is Driving the Liver Segment Growth

Liver cancer, particularly hepatocellular carcinoma (HCC), remains the leading indication for ablation procedures due to its high prevalence globally and the effectiveness of techniques like radiofrequency ablation (RFA) and microwave ablation (MWA) in treating localized tumors. Also, liver cancer is a significant concern in the UK, with around 6,600 new cases diagnosed each year, which equates to approximately 18 new cases every day. Despite being the 17th most common cancer in the UK, liver cancer accounts for 2% of all new cancer cases in the country. It is particularly notable for its growing prevalence, with a steady rise in incidence rates over the past decade. Among females in the UK, liver cancer ranks as the 20th most common cancer, with approximately 2,200 new cases reported annually. The ablation methods offer advantages such as minimal recovery time, reduced complications, and the ability to treat patients who are not candidates for surgery. Technological advancements in imaging and device precision have further improved the success of these treatments, making them highly effective in targeting tumors, especially in challenging anatomical regions like the liver. While liver cancer dominates the market, other cancers such as lung, kidney, and pancreatic cancer also contribute to market demand.

Interventional Oncology Ablation Market Analysis & Forecast, by End User: Institutional Investment in Oncology Infrastructure and Decentralized Care Models

Blood Hospitals and Clinics produce the largest amount of ablation procedures resulting in more than 60% of overall treatments. The healthcare facilities maintain the imaging systems that make ablation processes possible in precise ways. Several government hospitals throughout Germany together with Japan have built new oncology ablation facilities since the year 2020. Also, in February 2024, AIIMS Delhi launched a new AI solution for early cancer detection, developed in collaboration with the Centre for Development of Advanced Computing, Pune, under the Ministry of Electronics and Information Technology. The AI system utilizes deep learning models to analyze complex medical data with exceptional accuracy. These factors are further positively influencing the interventional oncology ablation market forecast.

Regional Insights

To learn more about this report, Request sample copy

North America Interventional Oncology Ablation Market Trend

The ablation sector in North America will rule the global market as it will hold a 33.5% stake in 2025 because of how the region quickly implements modern technologies and has supportive fee reimbursement systems and effective regulations. In July 2024, Varian, a company based in United States, received 510(k) clearance from the U.S. FDA for its IntelliBlate microwave ablation system, designed for soft tissue ablation. The system offers clinicians enhanced predictability, precision, and control during procedures, and is a key component of an integrated microwave ablation ecosystem. These factors are further escalating the interventional oncology ablation market demand in North America.

Europe Interventional Oncology Ablation Market Trends

The European interventional oncology ablation market is experiencing robust growth, driven by several key factors. Technological advancements, such as the introduction of directional microwave ablation (MWA) and the Isolis cryoprobe, are enhancing procedural precision and expanding treatment options for challenging tumors. For example, the Philips' "Azurion" platform, combining advanced imaging with precise ablation tools, is improving treatment outcomes. The increasing preference for minimally invasive procedures, such as radiofrequency ablation (RFA) for liver cancer, offers benefits like reduced recovery times and lower complication rates. Additionally, favorable reimbursement policies in countries like France and Germany are improving patient access to these advanced treatments, further accelerating the interventional oncology ablation market growth.

Germany Interventional Oncology Ablation Market Trends

Germany's interventional oncology ablation market is growing due to the increasing demand for minimally invasive surgery in cancer treatments and technological advancements. The use of advanced imaging techniques, such as CT and MRI-guided ablation, has significantly improved the accuracy and effectiveness of procedures. For example, the integration of tools like the IceCube cryoablation system has revolutionized the treatment of tumors by enabling precise, targeted destruction of cancerous tissue. Moreover, Germany’s healthcare system, which supports early cancer detection and offers favorable reimbursement for interventional oncology procedures, ensures greater access to these life-saving treatments. The rising number of cancer diagnoses in the country further drives this demand.

France Interventional Oncology Ablation Market Trends

France's interventional oncology ablation market is experiencing significant growth, driven by several key factors. The French government has implemented policies to enhance access to advanced medical technologies, including tumor ablation procedures. Initiatives such as reimbursement schemes for minimally invasive treatment options and investment in healthcare infrastructure contribute to the growth of the tumor ablation market. Also, in May 2024, Clinical Laserthermia Systems AB (CLS) announced an exclusive distribution agreement with MTEC Company to market and sell the CLS TRANBERG® product portfolio in France. The partnership will focus on launching the TRANBERG system for ultrasound-guided focal laser ablation (FLA) of localized prostate cancer, utilizing temperature control technology. This is further propelling the interventional oncology ablation market revenue.

 Interventional Oncology Ablation Market Trend

Integration of Precision Technology and Evolving Clinical Practices

Precision navigation systems together with real-time image guidance represents the main trend shaping Interventional Oncology Ablation market growth. The effectiveness of tumor targeting receives assistance from 3D imaging systems that work together with robotic-needed placement devices to maintain high safety standards when targeting hard-to-reach anatomical areas. Non-operable tumor ablation procedures experience growing popularity as a trend in the market. More oncologists choose ablation as a treatment method for nonsurgical candidates to apply this technique toward lung and renal and bone tumor metastases. The expansion occurs because procedures yield improved results while patients stay in the hospital for reduced durations.

Multiple studies focus on investigating different options available in interventional oncology ablative procedures. The healthcare institutions of Cleveland Clinic together with Tata Memorial Hospital now publish joint reports to analyze outcomes from microwave ablation against radiofrequency ablation treatments in hepatic and pulmonary malignancies. Healthcare institutions are now designing new protocols to evaluate patients after interventional oncology procedures. Healthcare institutions have developed better protocols for post-ablation imaging follow-up with MRI along with PET-CT to check treatment success and track tumor regrowth thus advancing extended patient surveillance capabilities.

Research about sustainability between reusable and disposable ablation probes motivates manufacturers to create new ablation probe designs which support hospital waste reduction requirements and procurement policies.

Interventional Oncology Ablation Market Drivers

Rising Prevalence of Cancer

The worldwide cancer incidence shows the most prominent effect on interventional oncology ablation market expansion. The Global Cancer Observatory predicts a substantial increase in new cancer cases up to 20 million every year through 2025 while liver cancer and lung cancer and kidney cancer will show the highest growth rates. The increasing case numbers in the population stimulates demand for tumor ablation treatments performed as localized minimally invasive procedures. Outpatient cancer care trends triggered the rapid implementation of ablation procedures in ambulatory surgical centers as well as smaller oncology clinics. The limited recovery time as well as associated minor complications of ablation make it a preferred choice in these treatment facilities over open surgical procedures, further accelerating the interventional oncology ablation market growth. 

Interventional Oncology Ablation Market opportunities

The Interventional Oncology Ablation Market presents its biggest possibilities when image-guided ablation needs expansion to low- and middle-income countries (LMICs). Ablative treatment methods provide LMICs with an affordable healthcare solution because they can be administered in facilities with basic equipment combined with outpatient facilities to address growing cancer cases.

The Brazilian along with Indian and South African governments initiate public funding for their cancer screening and localized treatment systems through purchases of microwave and radiofrequency ablation equipment. WHO’s global strategy to reduce premature cancer mortality through early detection and treatment supports these programs.

Through their investments the World Bank together with regional banks are helping construct healthcare infrastructure to build interventional oncology services in LMICs. The provided funding allows manufacturers to collaborate with public health systems for deploying mobile compact ablation units which function in areas without access to specialized imaging technology.

Interventional Oncology Ablation Market Challenges: Challenges Hindering Standardization and Global Adoption

A set of multidimensional barriers exists to affect the growth trajectory of Interventional Oncology Ablation Market. Low- and middle-income nations face restricted use of advanced ablation procedures because of high equipment expense and insufficient specialized providers and improper imaging facilities. Various regulatory differences accompany reimbursement restrictions which impede widespread adoption of procedures particularly outside hospital facilities and outpatient care centers. Apart from this, lack of standard operating procedures and varying performance of medical devices between manufacturers causes compatibility issues between systems while decreasing physician trust in the system. The requirement of experienced operators who must undergo continuous training creates significant barriers when these professionals are scarce in particular markets.

Market Report Scope

Interventional Oncology Ablation Market News

• In May 2025, RaySearch Laboratories launched the v2025 version of its RayStation treatment planning system. Key features include the Plan Explorer module, which automatically generates multiple treatment plans with various trade-offs and combinations of techniques and machines. The update also introduces RayStation Ablation for enhanced liver ablation guidance.
• In September 2024, EDAP TMS SA, a leader in robotic energy-based therapies, partnered with AI healthcare company Avenda Health to offer personalized prostate cancer care. The collaboration will use Avenda’s Unfold AI technology to launch AI-assisted Focal One robotic high-intensity focused ultrasound (HIFU) procedures. By integrating Unfold AI’s planning capabilities with the Focal One HIFU platform, the partnership aims to help urologists deliver more tailored, patient-specific HIFU ablation treatments for prostate cancer.
• In July 2024, Techsomed Ltd. launched its BioTrace software suite in the U.S., featuring BioTraceIO Vision and BioTraceIO Precision solutions. Both products, which received FDA clearance for liver tumor ablation last year, are now being implemented at top medical institutions, providing patients access to these advanced technologies.
• In April 2024, Sonablate introduced its innovative HIFU (High-Intensity Focused Ultrasound) technology at Kokilaben Dhirubhai Ambani Hospital (Mumbai) and Rajiv Gandhi Cancer Institute (Delhi). This minimally invasive, robotic device delivers precise ablative energy for prostate conditions, offering a radiation-free, bloodless ablation with significantly shorter recovery times.

Analyst Opinion (Expert Opinion)

• The migration of ablation technology from tertiary healthcare institutions into outpatient facilities and ambulatory settings occurs because these approaches yield better safety metrics combined with higher precision and reduced recovery times.
• The healthcare sector has significantly increased research and development investments aimed at developing microwave and cryoablation and irreversible electroporation tumor ablation techniques.
• AI-integrated systems together with robotic-assisted technologies improve accuracy rates when treating tumors that appear in complex anatomical areas of the lung and pancreas.
• Multiple healthcare experts from oncology and pulmonology and radiology continue to work together for creating integrated cancer treatment approaches.
• Manufacturers who focus on making affordable machines suitable for use by untrained personnel and offer portable forms will successfully break into emerging markets of Asia Africa and Latin America.
• Medical advancements and technology accessibility create conditions for ablation to emerge as a standard approach to cancer treatment worldwide.

Market Segmentation

• Technology Insights (Revenue, USD Mn, 2020 - 2032)
  • Radiofrequency Ablation (RFA)
  • Microwave Ablation (MWA)
  • Cryoablation
  • Irreversible Electroporation (IRE)
• Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer
  • Bone Metastases
  • Others
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Academic Medical & Research Institutes
  • Specialty Oncology Centers
  • Others
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Boston Scientific Corporation
  • Johnson & Johnson (Ethicon)
  • Medtronic Plc
  • Varian Medical Systems, Inc.
  • EDAP TMS S.A
  • AngioDynamics
  • CASCINATION AG
  • Merit Medical Systems, Inc. –
  • STARmed Co.
  • Biomedical Srl

Sources

 Primary Research Interviews from the following stakeholders:

Stakeholders:

• Interviews with medical professionals, device manufacturers, healthcare providers, and industry experts specializing in interventional oncology and ablation technologies.
• Specific stakeholders: Interventional radiologists, oncologists, biomedical engineers, healthcare administrators, and surgical specialists involved in cancer diagnostics and treatment planning

Databases:

• PubMed
• ClinicalTrials.gov
• HealthData.gov

Magazines:

• MedTech Insight
• Healthcare Technology News
• Medical Device and Diagnostic Industry (MD+DI)
• HealthTech Magazine

Journals:

• Journal of Vascular and Interventional Radiology
• Journal of Medical Devices
• Biomed Optics Express
• Journal of Clinical Oncology

Newspapers:

• The New York Times
• The Guardian
• The Wall Street Journal
• Financial Times
• The Washington Post

Associations:

• Society of Interventional Radiology (SIR)
• American Society of Clinical Oncology (ASCO)
• Medical Device Manufacturers Association (MDMA)
• International Liver Cancer Association (ILCA)
• American Cancer Society (ACS)

Public Domain Sources:

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• Food and Drug Administration (FDA)
• National Institutes of Health (NIH)

Proprietary Elements:

• CMI Data Analytics Tool, and Proprietary CMI Existing Repository of information for the last 8 years.